切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2026, Vol. 12 ›› Issue (03) : 267 -271. doi: 10.3877/cma.j.issn.2096-1537.2026.03.006

年度进展

急性呼吸窘迫综合征表型及药物治疗的研究进展
史楠, 袁雪燕, 刘玲, 邱海波†()   
  1. 210009 南京,江苏省重症医学重点实验室 东南大学附属中大医院重症医学科
  • 收稿日期:2026-05-08 出版日期:2026-08-28
  • 通信作者: 邱海波
  • 基金资助:
    四大慢病国家科技重大专项(2024ZD0530000,2023ZD0506500); 国家自然科学基金项目(U25C2018,82470079,82270083); 教育部基础学科和交叉学科突破计划项目(JYB2025XDXM506); 江苏省科技计划项目“省前沿技术研发计划”项目(BF2024054); 江苏省器官衰竭与重建重点实验室项目(ZDXYS202205)

Advances in phenotyping and pharmacotherapy of acute respiratory distress syndrome

Nan Shi, Xueyan Yuan, Ling Liu, Haibo Qiu†()   

  1. Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
  • Received:2026-05-08 Published:2026-08-28
  • Corresponding author: Haibo Qiu
引用本文:

史楠, 袁雪燕, 刘玲, 邱海波. 急性呼吸窘迫综合征表型及药物治疗的研究进展[J/OL]. 中华重症医学电子杂志, 2026, 12(03): 267-271.

Nan Shi, Xueyan Yuan, Ling Liu, Haibo Qiu. Advances in phenotyping and pharmacotherapy of acute respiratory distress syndrome[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(03): 267-271.

本文回顾了2025年度急性呼吸窘迫综合征(ARDS)表型及药物治疗的代表性科学研究进展。该领域的诊疗重心正从基于指南的常规策略转向基于个体治疗效应的精准干预策略。多组学维度的研究深化了对高/低炎症表型生物学异质性的认知,其中,基于蛋白质组学分类器的表型界定,为高危人群的早期识别提供了有效工具。药物治疗方面,疗效异质性分析发现单一炎症指标具有指导糖皮质激素治疗决策的潜在价值,神经肌肉阻滞剂在特定生理表型(高弹性阻力、年轻及合并症少)中的生存优势亦获证实。尽管吸入镇静与间充质干细胞治疗ARDS的临床价值仍存在争议,但其研究方向已聚焦于潜在获益表型的探索。可见,突破普适性治疗的局限是解决ARDS治疗瓶颈的核心所在。通过多组学背景下的患者分层和临床与生物学参数的精准富集,构建针对特定生物表型的个体化干预路径,将是实现ARDS精准化药物治疗的关键。

This review highlights critical scientific research advancements in the field of phenotypes and pharmacological treatments for acute respiratory distress syndrome (ARDS) in 2025. The clinical paradigm in this field has shifted from guideline-based conventional strategies toward precision intervention strategies grounded in individual treatment effects. Multiomic analysis has deepened the understanding of biological heterogeneity underlying hyperinflammatory and hypoinflammatory phenotypes, wherein parsimonious proteomics-based classifiers have emerged as critical tools for the early identification of high-risk populations. In the domain of pharmacotherapy, heterogeneity of treatment effect analysis suggested the feasibility of using a single inflammatory biomarker to guide corticosteroid treatment decisions. While the survival benefit of neuromuscular blockade has been confirmed in specific physiological phenotypes characterized by high respiratory system elastance, younger age, and fewer comorbidities. Although the clinical utility of inhaled sedation and mesenchymal stem cell therapy in ARDS remains undefined, ongoing research has increasingly converged on the identification of phenotypes with potential therapeutic benefit. In conclusion, overcoming the inherent limitations of one-size-fits-all treatment approaches is central to resolving the therapeutic bottleneck in ARDS. Achieving precision pharmacotherapy requires paradigms moving beyond population-level treatment. Multiomic-driven stratification, combined with precise enrichment of clinical or biological parameters, enables the construction of individualized intervention pathways tailored to specific biological phenotypes.

1
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials[J]. Lancet Respir Med, 2014, 2(8): 611-620.
2
Sinha P, Delucchi KL, McAuley DF, et al. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials[J]. Lancet Respir Med, 2020, 8(3): 247-257.
3
Dahmer MK, Yang G, Zhang M, et al. Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis[J]. Lancet Respir Med, 2022, 10(3): 289-297.
4
Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials[J]. Lancet Respir Med, 2023, 11(11): 965-974.
5
Sarma A, Christenson SA, Shoshana BZ, et al. Acute Respiratory Distress Syndrome Molecular Phenotypes Have Distinct Lower Respiratory Tract Transcriptomes[J]. Am J Respir Crit Care Med, 2025, 211(12): 2352-2362.
6
Lin M, Xu F, Deng Y, et al. Large-scale proteomic profiling identifies distinct inflammatory phenotypes in Acute Respiratory Distress Syndrome (ARDS): a multi-center, prospective cohort study[J]. Eur Respir J, 2026, 67(2): 2500933.
7
Alipanah-Lechner N, Neyton L, Sinha P, et al. Longitudinal multiomic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality[J]. J Clin Invest, 2025, 136(3): e196290.
8
Pensier J, Fosset M, Paschold BS, et al. Temporal stability of phenotypes of acute respiratory distress syndrome: clinical implications for early corticosteroid therapy and mortality[J]. Intensive Care Med, 2025, 51(10): 1784-1796.
9
Nasa P, Bos LD, Estenssoro E, et al. Defining and subphenotyping ARDS: insights from an international Delphi expert panel[J]. Lancet Respir Med, 2025, 13(7): 638-650.
10
Reddy K, Sinha P, Antcliffe DB, et al. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study[J]. Lancet Respir Med, 2026: S2213-2600(26)00040-8.
11
Delucchi K, Famous KR, Ware LB, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials[J]. Thorax, 2018, 73(5): 439-445.
12
Renard Triché L, Fosset M, Jabaudon M, et al. Temporal stability of inflammatory subphenotypes of acute respiratory distress syndrome: 28-day insights from the ICAR trial[J]. Anaesth Crit Care Pain Med, 2025, 44(5): 101559.
13
van Amstel RBE, Bartek B, Vlaar APJ, et al. Temporal transitions of the hyperinflammatory and hypoinflammatory phenotypes in critical illness[J]. Am J Respir Crit Care Med, 2025, 211(3): 347-356.
14
Munroe ES, Spicer A, Castellvi-Font A, et al. Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill[J]. Lancet Respir Med, 2025, 13(6): 556-568.
15
Graham Linck EJ, Goligher EC, Semler MW, et al. Toward precision in critical care research: methods for observational and interventional studies[J]. Crit Care Med, 2024, 52(9): 1439-1450.
16
Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial[J]. Lancet Respir Med, 2020, 8(3): 267-276.
17
Smit JM, Van Der Zee PA, Stoof SCM, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials[J]. Lancet Respir Med, 2025, 13: 221-233.
18
Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial[J]. JAMA, 2015, 313(7): 677-686.
19
Michels EHA, Dequin PF, Butler JM, et al. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial[J]. Lancet Respir Med, 2026, 14(4): 327-340.
20
Smit JM, Krijthe JH, Lloyd M, et al. From severity-guided to CRP-guided corticosteroid treatment[J]. Am J Respir Crit Care Med, 2026: aamag070.
21
Jones BE, Ramirez JA, Oren E, et al. Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2026, 212(1): 24-44.
22
Soumare A, Kapfer T, Botrel T, et al. Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome : A Systematic Review and Meta-analysis[J]. Ann Intern Med, 2026, 179(1): 67-80.
23
Reyes LF, Martin-Loeches I. Corticosteroids in community-acquired pneumonia: a step forward, but questions remain[J]. Lancet Respir Med, 2025, 13(3): 191-193.
24
Smit JM, Krijthe JH, Meduri GU, et al. C-reactive protein-guided treatment in pneumonia: charting a personalised approach - Authors' reply[J]. Lancet Respir Med, 2025, 13(5): e25-e26.
25
Meiser A, Volk T, Wallenborn J, et al; Sedaconda study group. Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial[J]. Lancet Respir Med, 2021, 9(11): 1231-1240.
26
Jabaudon M, Quenot JP, Badie J, et al. Inhaled sedation in acute respiratory distress syndrome: the SESAR randomized clinical trial[J]. JAMA, 2025, 333(18): 1608-1617.
27
Zalucky AA, Dianti J, Neyton LPA, et al. Elastance may determine the neuromuscular blockade effect on mortality in acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2025, 211(6): 966-974.
28
Brunini M, Forel JM, Muracciole X, et al. Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial[J]. Intensive Care Med, 2025, 51(9): 1615-1627.
29
Goligher EC, Costa ELV, Yarnell CJ, et al. Effect of lowering Vt on mortality in acute respiratory distress syndrome varies with respiratory system elastance[J]. Am J Respir Crit Care Med, 2021, 203(11): 1378-1385.
30
Lakbar I, De Jong A, Battaglini D. Refining the use of neuromuscular blockade in ARDS: lessons from a post hoc Markov model re-analysis of the ACURASYS trial[J]. Intensive Care Med, 2025, 51(12): 2399-2402.
31
de Grooth HJ, Yehya N, Harhay MO. Credible subgroup effects in randomized clinical trials[J]. Am J Respir Crit Care Med, 2025, 211(6): 893-895.
32
Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value[J]. Am J Respir Crit Care Med, 2017, 196(3): 266-273.
33
Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial[J]. Lancet Respir Med, 2019, 7(2): 154-162.
34
Matthay MA, Zhuo H, Sarma A, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome: a double-blind, placebo-controlled, multicenter phase 2b clinical trial (STAT)[J]. Am J Respir Crit Care Med, 2026, 212(3): 428-439.
35
Wu Y, Xu R, Li Y, et al. Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis[J]. Stem Cell Res Ther, 2025, 16(1): 522.
[1] 丁彩霞, 曲景辉, 裴英宏, 李静娜, 郑晓瑜, 徐岭植, 李思思. 基于RNA结合蛋白基因表达特征的乳腺癌预后预测模型构建及评价分析[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(03): 138-147.
[2] 王美衡, 李杰, 陈策实, 许超汉. 乳腺癌串联重复表型的识别及分子功能特征分析[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(03): 148-155.
[3] 刘濠瑞, 甘靖, 范丽娟. 先天性糖基化障碍相关儿童癫痫的致痫机制与临床诊疗[J/OL]. 中华妇幼临床医学杂志(电子版), 2026, 22(04): 354-363.
[4] 张阿妮, 王冠华, 袁亚迎, 任志超, 梁杰, 赵蕊新, 陈妍, 郭娟妮, 康瑞. 肺超声联合膈肌超声检测指标预测急性呼吸窘迫综合征患者拔管的临床研究—附126例分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 392-398.
[5] 甘志新, 胡雍军, 杨倩, 胡明冬. 75例急性呼吸窘迫综合征的临床特征及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 221-226.
[6] 梅春霞, 冯霞, 邬海桥, 刘攀, 李昆霖, 徐智, 刘禹. 肺损伤预测评分联合血管生成素-2对肺部感染并发急性呼吸窘迫综合征的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(01): 9-14.
[7] 王辉, 孙咏琪. 儿童遗传性肾脏病再认识[J/OL]. 中华肾病研究电子杂志, 2026, 15(01): 8-14.
[8] 娄熙冉, 袁雪燕, 邱海波, 刘玲. 急性呼吸窘迫综合征机械通气的研究进展[J/OL]. 中华重症医学电子杂志, 2026, 12(03): 262-266.
[9] 伍宵, 唐颖, 张曦文, 邱海波. 表观遗传修饰调控急性呼吸窘迫综合征发病机制的研究进展[J/OL]. 中华重症医学电子杂志, 2026, 12(02): 202-207.
[10] 张莉, 谢剑锋, 张学超, 王静, 王伟, 钱淑媛. 重度急性呼吸窘迫综合征患者客观评估导向的精准化镇痛镇静一例[J/OL]. 中华重症医学电子杂志, 2026, 12(02): 214-218.
[11] 罗钰莹, 陈洁. 慢病人群呼吸机依赖精准干预体系的构建及实施路径[J/OL]. 中华重症医学电子杂志, 2026, 12(01): 25-30.
[12] 张容, 许家璇, 叶伟炎, 刘学松, 刘晓青. 以慢病为核心的呼吸机依赖预测探索:从表型多样到人工智能赋能[J/OL]. 中华重症医学电子杂志, 2026, 12(01): 42-45.
[13] 于丽娜, 张晓丽, 胡继宽, 张广稳, 钱会涛, 丁喜珍, 张颖, 陈齐红. 西维来司他钠调节Th17/Treg平衡改善多发伤相关ARDS患者氧合的随机对照研究[J/OL]. 中华临床医师杂志(电子版), 2025, 19(12): 919-925.
[14] 彭坤, 冯辉斌, 袁利学. 急性有机磷农药中毒并发急性呼吸窘迫综合征的危险因素相关性[J/OL]. 中华临床医师杂志(电子版), 2025, 19(09): 668-674.
[15] 张立, 李巧妮, 贺帅, 王朝霞, 宁小康. 连续性血液净化联合血液灌流在严重脓毒症合并急性呼吸窘迫综合征患者中的应用效果及PCT、hs-CRP、IL-6水平影响[J/OL]. 中华卫生应急电子杂志, 2026, 12(01): 26-31.
阅读次数
全文


摘要


AI
小
编
AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?